Product Description
Gaboxadol (OV101) is a delta-subunit–selective, extrasynaptic GABAA receptor agonist that enhances GABAergic tonic inhibition, providing the rationale for assessment of OV101 as a potential targeted treatment of FXS. No drug is approved in the United States for the treatment of FXS. (Sourced from: https://www.frontiersin.org/articles/10.3389/fphar.2021.757825/full#:~:text=Gaboxadol%20(OV101)%20is%20a%20%CE%B4,for%20the%20treatment%20of%20FXS.)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ovid
Company Location: NEW YORK NY 10036
Company CEO: Jeremy M. Levin
Additonal Commercial Interests: Healx
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Fragile X Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06334419 | P2 |
Recruiting |
Fragile X Syndrome |
2024-09-30 |